Findings

What do systematic reviews say?

7 questions · 7 findings · 1 reviews

Sort:Best matchNewest Highest certainty Download CSV

No studies found 2 · 28.6%GRADE not reported 0 · 0%Very low 0 · 0%Low 5 · 71.4%Moderate 0 · 0%High 0 · 0%

Oral viscous budesonide vs swallowed fluticasone

Clinical improvement (dichotomous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral viscous budesonide vs swallowed fluticasone

Clinical improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 84 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Histological improvement (dichotomous) · active EoE patients

Oral viscous budesonide showed no clear difference in histological improvement at study endpoint (dichotomous) compared with swallowed fluticasone (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 1.13 [0.84, 1.51]
1 study · 129 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Histological improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Endoscopic improvement (dichotomous) · active EoE patients

The review found no eligible studies for this question.

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
Studies not reported
No studies found

Oral viscous budesonide vs swallowed fluticasone

Endoscopic improvement (continuous) · active EoE patients

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
no estimate extracted
1 study · 111 participants
Low

Oral viscous budesonide vs swallowed fluticasone

Withdrawals due to adverse events · active EoE patients

Oral viscous budesonide showed no clear difference in withdrawals due to adverse events at 8 weeks compared with swallowed fluticasone (low certainty).

1 finding from 1 review

Medical treatment of eosinophilic esophagitis 2023 · Cochrane Headline outcomes only
RR 0.98 [0.42, 2.32]
1 study · 129 participants
Low